On May 22, 2023, the U.S. Food and Drug Administration (“FDA”) approved the first nalmefene hydrochloride prescription nasal spray for the emergency treatment of opioid poisoning in adults and pediatric patients aged 12 years or older.
With the persistence of drug poisonings as a major public health issue within the United States, the new treatment can aid in mitigating fatal poisonings if administered quickly enough through reversing the effects of opioid poisonings. It is the first nalmefene hydrochloride nasal spray approved by the FDA for healthcare and community usage.
Read the full news release here.